Search the Newsreel

Pulmatrix posts Q2 2026 net loss $1.04M, cash $2.2M; files Form S-4 for Eos merger

Pulmatrix reported a Q2 2026 net loss of $1.04 million and held $2.2 million in cash and cash equivalents. The company has filed a Form S-4 in relation to its proposed merger with Eos SENOLYTIX, which is expected to close in Q3 2026. Clinical …

Pulmatrix Announces Second Quarter 2026 Financial Results and Progress on Merger

Pulmatrix, Inc. announced its second-quarter 2026 financial results and provided an update on its proposed merger with Eos SENOLYTIX, which is expected to close in Q3 2026. The company is focusing on advancing the merger while also seeking to out-license or monetize its clinical …

Form 8K Pulmatrix Inc For: 13 August By Investing.com

This article announces that Pulmatrix Inc. filed a Form 8K on August 13. The brief piece from Investing.com indicates that the filing pertains to the company PULM, which saw a -5.06% change. No further details about the content of the Form 8K are provided.

Pulmatrix Says $2.2M Cash Could Fund Operations Through Eos Merger

Pulmonx (LUNG) Q2 2026 Earnings Call Transcript

Pulmonx (LUNG) reported its Q2 2026 earnings, highlighting a 34% reduction in net loss and a 39% decrease in adjusted EBITDA loss, driven by cost alignment initiatives. The company reiterated its full-year revenue guidance of $90 million to $92 million and expects to return …

Pulmatrix Inc (PULM) Stock News Today

Pulmatrix Inc (PULM) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Pulmatrix Inc (PULM), noting that no earnings forecast score is currently available for the company. It mentions the Biotechnology & Medical Research industry average score and includes a section on analyst ratings, though no specific ratings are …

Pulmonx Corp 2026: Revenue $22.76M, EPS ($0.24) — 10-Q Summary

Pulmonx Corp reported its 2026 quarterly results, showing revenue of $22.76 million and a diluted EPS of ($0.24), an improvement from the prior year. The company experienced a decline in revenue due to lower procedure volumes, particularly in the U.S. and China, but saw …

Pulmonx (LUNG) Upgraded to Buy: What Does It Mean for the Stock?

Pulmonx (LUNG) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in earnings estimates. The Zacks rating system highlights the strong correlation between changes in future earnings potential and near-term stock price movements, suggesting positive investor sentiment and potential …

Earnings Release: Here's Why Analysts Cut Their Pulmonx Corporation (NASDAQ:LUNG) Price Target To US$3.40

Pulmonx Corporation's Q2 results showed revenues in line with predictions and smaller-than-expected statutory losses. Despite the positive earnings surprise, analysts have lowered their average price target to US$3.40, indicating reduced optimism about the company's future valuation. While revenue growth is expected to slow, it …

Pulmonx Corporation Revenue Breakdown – NASDAQ:LUNG

Pulmatrix Inc (PULM) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Pulmatrix Inc (PULM), ranking its financial status as robust with a score of 6.80 within the Biotechnology & Medical Research industry. Key financial dimensions like Quality of Earnings and Shareholder Returns are also rated. However, several financial …

Lake Street Maintains Pulmonx(LUNG.US) With Buy Rating, Maintains Target Price $4

Lake Street has reiterated its Buy rating for Pulmonx (LUNG.US) and maintained its price target at $4. This indicates a continued positive outlook from the firm regarding the company's stock performance.

Pulmatrix Inc (PULM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Pulmatrix Inc (PULM), stating its current valuation score is 6.63, ranking 276 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -1.40, noting it is significantly below its …

Pulmatrix Inc (PULM) Income Statement

This article provides the quarterly and annual income statements for Pulmatrix Inc (PULM), detailing financial performance metrics such as total revenue, operating expenses, and net income. It also includes frequently asked questions about how to interpret these financial statements and key metrics for analyzing …

Pulmonx Affirms FY26 Sales Guidance of $90.000M-$92.000M

Pulmonx (NASDAQ: LUNG) has reiterated its full-year 2026 sales guidance, keeping the range at $90.000 million to $92.000 million. This guidance is consistent with previous statements and aligns closely with the consensus analyst estimate of $90.832 million. The affirmation signals management's confidence in the …

Pulmonx Corp Q2 revenue falls, but beats estimates

Pulmonx Corp's Q2 revenue experienced a decline but still managed to surpass analyst estimates. The article, sourced from Reuters via TradingView News, provides a brief update on the company's financial performance.

Pulmonx Corporation (LUNG) Reports Q2 Loss, Beats Revenue Estimates

Pulmonx Corporation (LUNG) reported a Q2 loss of $0.24 per share, surpassing the Zacks Consensus Estimate of a $0.28 loss, and also beat revenue expectations with $22.76 million. Despite underperforming the market year-to-date, the company has consistently topped revenue estimates in the past four …

BlackRock (LUNG) updates Pulmonx Corp stake, reports 765,721 shares owned

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 765,721 shares of Pulmonx Corp (LUNG) common stock, which represents 1.8% of the class. BlackRock holds sole voting and sole dispositive power over all these shares, with no shared power. The …

Pulmonx (NASDAQ:LUNG) Announces Earnings Results

Earnings call transcript: Pulmonx tops Q2 2026 estimates, shares jump 14.4%

Pulmonx Corp. Revenue Breakdown – LSX:A2P1AF

Pulmonx Corp. (LSX:A2P1AF) generated €77.05 million in revenue last year, primarily from its Interventional Pulmonology segment. The United States was the largest contributor to revenue, accounting for €48.55 million in the past year. This report provides a breakdown of the company's financial performance by …

Pulmonx's Aug. 11 Boston fireside chat will be webcast live

Pulmonx (Nasdaq: LUNG) announced it will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the event will be …

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Pulmonx Corporation will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on August 11, 2026. The event, taking place in Boston, will also be accessible via a live and archived webcast on the "Investors" section of the company's website. …

LUNG|Pulmonx Corp|Price:1.225|Chg%:+0.055

This article from TradingKey provides a comprehensive stock analysis of Pulmonx Corp (LUNG), highlighting its relatively healthy fundamentals, significant growth potential, and "fairly valued" status within the Healthcare Equipment & Supplies industry. It notes high institutional ownership and recent "Buy" ratings from analysts with …

PULM|Pulmatrix Inc|Price:1.670|Chg%:-0.060

This article provides a comprehensive stock analysis of Pulmatrix Inc (PULM) from TradingKey, highlighting its healthy fundamentals, high growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes strong institutional ownership and a medium-term upward trend expectation for the …

Pulmonx Corp (LUNG) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Pulmonx Corp (LUNG), listing its major shareholders and their proportions, as well as categorizing shareholder types. It also provides institutional shareholding data over several quarters and recent shareholder activity. Additionally, the article lists related ETFs that include …

Pulmonx Corp expected to post a loss of 28 cents a share - Earnings Preview

Pulmonx Corp (NASDAQ: LUNG) is anticipated to report a loss of 28 cents per share in its upcoming earnings announcement. This information, provided by Refinitiv, suggests the company is facing an expected negative financial outcome for the period.

Pulmatrix Inc (PULM) Cash Flow

This article provides a detailed cash flow statement for Pulmatrix Inc (PULM), covering quarterly and annual data from FY2013Q1 to FY2026Q1. It breaks down operating, investing, and financing cash flows, along with changes in working capital and net income from continuing operations. The document …

Pulmatrix Inc (PULM) Institutional Confidence

Pulmatrix Inc (PULM) has an institutional shareholding score of 3.00, placing it 191st out of 384 companies in the Biotechnology & Medical Research industry. The institutional shareholding proportion has increased by 8.89% quarter-over-quarter, reaching 10.12%. James Simons is the largest institutional shareholder, holding 2.99% …

Pulmatrix Inc (PULM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Pulmatrix Inc (PULM) stock information, focusing on its dividend history and stock split events. It indicates that the company has not distributed dividends in the past five years and lists multiple stock splits that occurred on February 25, …

Pulmonx Market Sentiment

This article analyzes the market sentiment for Pulmonx (LUNG) based on analyst consensus, short interest, options flow, and insider activity. It highlights a "Buy" consensus from 9 analysts with an average price target of $8, a 3.2% short float, and no recent insider activity. …

Pulmonx Corp. Revenue Breakdown – MUN:4NI

This article provides a revenue breakdown for Pulmonx Corp. (MUN:4NI), showing that its top-performing segment, Interventional Pulmonology, generated €77.05 million last year, down from €80.94 million in the prior year. The United States was the greatest contributor, accounting for €48.55 million, a decrease from …